Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A softer path for kidney disease: could palliative care ease the burden?

NCT ID NCT07741357

Symptom relief Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests whether adding palliative care to standard treatment helps people with advanced chronic kidney disease (stages 4 and 5, including those on dialysis) feel better. Participants are randomly assigned to receive either usual kidney care or usual care plus integrated kidney palliative care, which focuses on managing symptoms, understanding illness, planning future care, and addressing social or spiritual needs. The study tracks changes in symptom burden and quality of life to see if this extra layer of support makes a meaningful difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Integrated kidney palliative care (a behavioral intervention combining symptom assessment, goals-of-care discussions, advance care planning, and social/spiritual support)
What this could lead to
If it works, this approach could become a standard part of kidney care, helping people with advanced chronic kidney disease feel better day-to-day and live with less distress.
What could go wrong
The trial is still in an early phase, and the benefit may be modest or vary from person to person. Adding palliative care could also be hard to roll out widely in busy clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 280 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2027

An estimate. Start dates often move.

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Receive care at nephrology clinics or dialysis centers associated with each site. 2. Have CKD stage IV, V (eGFR \< 30 mL/min/1.73m2), or be receiving chronic dialysis 3. Speak Spanish or English, and report at IPOS-Renal score of ≥ 3 on a screening survey. 4. Willing to be randomized to either study arm and to comply with the study procedures for the assigned group. Exclusion Criteria: 1. Unable to provide informed consent 2. Has received palliative care (inpatient or outpatient) in the last six months. 3. Enrolled in hospice 4. Has any urgent palliative care needs (i.e. severe pain, emotional distress) identified upon screening. Research staff will be trained to recognize these needs. 5. Non-English and Non-Spanish speakers to correspond with the populations most impacted by CKD in the US. 6. Pregnant individuals.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease (stages 4 and 5) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease (stages 4 and 5)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30322, United States

  • NYU Langone Health

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.